Close
Help
Need Help?





JOURNAL

Clinical Medicine Insights: Therapeutics

868,939 Journal Article Views | Journal Analytics

A Review of Topical Imiquimod in the Management of Basal Cell Carcinoma, Actinic Keratoses, and Other Skin Lesions

Submit a Paper



Publication Date: 03 Nov 2009

Type: Review

Journal: Clinical Medicine Insights: Therapeutics

Citation: Clinical Medicine: Therapeutics 2009:1 1557-1575

Abstract

Imiquimod (trade name Aldara™) is a small molecule of the imidazoquinoline family, a group of nucleoside analogs that were first synthesized as potential antiviral agents. It has since been discovered to activate both innate and adaptive immunity, as well as apoptosis. Clinically, it has been approved for three indications thus far: external genital warts, actinic keratosis, and superficial basal cell carcinoma. In addition to these applications, a number of off-label uses have been reported in the literature. In this review, we summarize and discuss the literature describing imiquimod’s mechanism of action, its approved and off-label clinical uses, and its safety and tolerability.


Downloads

PDF  (672.64 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)




Our Service Promise

  • Prompt Processing (3 Weeks to Editorial Decision)
  • Fair, Independent Peer Review
  • High Visibility & Extensive Indexing
What Your Colleagues Say About Clinical Medicine Insights: Therapeutics
My publishing experience with Libertas was truly an enjoyable experience.  I really appreciate the rapid response to my questions and support that I received as an author. I would highly recommend Libertas to other authors.
Dr Wanda C Reygaert (Oakland University William, Beaumont School of Medicine, Rochester, MI, USA)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results